This position paper was commissioned by PETRA to look at how trade and investment agreements can impact the availability and pricing of medicines and pharmaceutical products. The paper argues the case for the UK not to include the stringent TRIPS+ intellectual property provisions in its trade agreements in order to determine a fair price for medicines.